AVM
JANX icon

Avalon Ventures Management’s Janux Therapeutics JANX Stock Holding History

Avalon Ventures Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.3M Buy
53,300
+10,000
+23% +$244K 9.17% 2
2025
Q2 		$1M Buy
+43,300
New +$1.14M 5.26% 2

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Avalon Ventures Management's JANX Position: Q3 2025 in Review

Avalon Ventures Management increased its Janux Therapeutics (JANX) stake by 23% in Q3 2025, buying an estimated $244K and bringing the position to 53,300 shares worth $1.3M. The position accounts for 9.17% of the portfolio, ranked #2.

Avalon Ventures Management first reported a position in JANX in Q2 2025 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Avalon Ventures Management held 53,300 shares of Janux Therapeutics worth $1.3M as of Q3 2025.
  • Avalon Ventures Management bought 10,000 Janux Therapeutics shares in Q3 2025, an estimated $244K.
  • Janux Therapeutics made up 9.17% of Avalon Ventures Management's portfolio in Q3 2025, its #2 holding.
  • Avalon Ventures Management first reported a position in Janux Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Avalon Ventures Management's 13F filing for Q3 2025, filed 13 Nov 2025.